Company Overview of Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics, Inc. develops new therapies and re-positions existing therapies to meet serious unmet needs. Its development portfolio includes Metformin DR, a delayed-release formulation of metformin that releases metformin primarily in the distal small intestine and restricts metformin to the bowel primarily suited for patients who cannot use metformin owing to contraindications or poor tolerability. The company’s Metformin DR solution serves as an initial agent for the treatment of type 2 diabetes. The company was incorporated in 2009 and is headquartered in San Diego, California.
11975 El Camino Real
San Diego, CA 92130
Founded in 2009
Key Executives for Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics, Inc. Key Developments
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Elcelyx Therapeutics, Inc., please visit elcelyx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.